Biomarin Pharmaceutical Inc.
14 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 8 name spellings.
35
Ending by 2030
Apr 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 16 to 28, 2026 · next Nov 16
- 2 fees due Dec 2 to 4, 2026 · next Dec 2
- 1 fee due Jan 4, 2027The maintenance fee for Adeno-Associated Virus Factor VIII Vectors, Associated Viral Particles and Therapeutic Formulations Comprising the Same (US 11,690,898) comes due Jan 4, 2027. Unpaid by Jul 6, 2027, it lapses early.
- 1 fee due Feb 28, 2027The maintenance fee for Methods of treating phenylketonuria (US 11,739,345) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due May 21, 2027The maintenance fee for Liver targeting adeno-associated viral vectors (US 11,821,008) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 4 fees due Jun 1 to 29, 2027 · next Jun 1
- 2 fees due Aug 18 to 27, 2027 · next Aug 18
- 1 fee due Sep 5, 2027The maintenance fee for Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects (US 11,918,633) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia (US 10,646,550) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
- 1 term has ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,612,073 | Methods of Administering Tetrahydrobiopterin, Associated Compositions, and Methods of Measuring In force · Low confidence | In force | Low confidence | |
| US RE43,797 | Methods of Administering Tetrahydrobiopterin In force · Low confidence | In force | Low confidence | |
| US 7,537,923 | Compositions of Prokaryotic Phenylalanine Ammonia-Lyase and Methods of Treating Cancer Using Compositions Thereof In force · Medium confidence | In force | Medium confidence | |
| US 7,560,263 | Compositions of Prokaryotic Phenylalanine Ammonia-Lyase and Methods of Treating Cancer Using Compositions Thereof In force · High confidence | In force | High confidence | |
| US 7,790,433 | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 7,713,709 | Assay for Detection of Antibodies to Lysosomal Enzymes In force · High confidence | In force | High confidence | |
| US 8,003,126 | Stable Tablet Formulation In force · Medium confidence | In force | Medium confidence | |
| US 7,722,865 | Manufacture of Active Highly Phosphorylated Human Lysosomal Sulfatase Enzymes and Uses Thereof In force · High confidence | In force | High confidence | |
| US 8,420,368 | Manufacture of Active Highly Phosphorylated Human Lysosomal Sulfatase Enzymes and Uses Thereof In force · High confidence | In force | High confidence | |
| US 10,934,534 | Manufacture of Active Highly Phosphorylated Human Lysosomal Sulfatase Enzymes and Uses Thereof In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 88: 14 patents in force now held by others · 40 lapsed for an unpaid fee · 35 ended at full term · 3 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
13 pending · 17 abandoned · 64 no status recorded